PRG-1801

BIOLOGICAL2 trials

Sponsors

Tongji Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions

IgG4-related DiseaseImmune ThrombocytopeniaLupus Nephritis

Early Phase 1

Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

RecruitingNCT06497387

Tongji HospitalIgG4-related Disease, Lupus Nephritis

Start: 2024-07-31End: 2028-07-31Target: 30Updated: 2024-07-11

Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)

RecruitingNCT06519565

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyImmune Thrombocytopenia

Start: 2024-08-20End: 2027-08-15Target: 6Updated: 2025-11-28

Related Papers

BCMA-targeted CAR T cells for multi-refractory primary immune thrombocytopenia: A pilot study

Blood2025-11-03